195 related articles for article (PubMed ID: 33558149)
1. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
Gaines H; Jones KR; Lim J; Medhi NF; Chen S; Scofield RH
J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis.
Cohen A; Mass A; Reiter J; Zangen DH; Cohen-Cymberknoh M
Respir Med; 2024 Jul; 228():107664. PubMed ID: 38759874
[TBL] [Abstract][Full Text] [Related]
3. Cystic fibrosis transmembrane conductance regulator modulators reduce the risk of recurrent acute pancreatitis among adult patients with pancreas sufficient cystic fibrosis.
Akshintala VS; Kamal A; Faghih M; Cutting GR; Cebotaru L; West NE; Jennings MT; Dezube R; Whitcomb DC; Lechtzin N; Merlo CA; Singh VK
Pancreatology; 2019 Dec; 19(8):1023-1026. PubMed ID: 31611131
[TBL] [Abstract][Full Text] [Related]
4. Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis.
Taelman V; Declercq D; Van Biervliet S; Weygaerde YV; Lapauw B; Van Braeckel E
Clin Nutr ESPEN; 2023 Dec; 58():73-78. PubMed ID: 38057039
[TBL] [Abstract][Full Text] [Related]
5. Advances in cystic fibrosis-related diabetes: Current status and future directions.
Lurquin F; Buysschaert M; Preumont V
Diabetes Metab Syndr; 2023 Nov; 17(11):102899. PubMed ID: 37939435
[TBL] [Abstract][Full Text] [Related]
6. The role of modulators in cystic fibrosis related diabetes.
Merjaneh L; Hasan S; Kasim N; Ode KL
J Clin Transl Endocrinol; 2022 Mar; 27():100286. PubMed ID: 34917484
[TBL] [Abstract][Full Text] [Related]
7. Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.
Guimbellot JS; Ryan KJ; Anderson JD; Liu Z; Kersh L; Esther CR; Rowe SM; Acosta EP
J Cyst Fibros; 2020 Sep; 19(5):742-745. PubMed ID: 32044246
[TBL] [Abstract][Full Text] [Related]
8. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.
Putman MS; Norris AW; Hull RL; Rickels MR; Sussel L; Blackman SM; Chan CL; Ode KL; Daley T; Stecenko AA; Moran A; Helmick MJ; Cray S; Alvarez JA; Stallings VA; Tuggle KL; Clancy JP; Eggerman TL; Engelhardt JF; Kelly A
Diabetes Care; 2023 Jun; 46(6):1112-1123. PubMed ID: 37125948
[TBL] [Abstract][Full Text] [Related]
9. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.
Putman MS; Norris AW; Hull RL; Rickels MR; Sussel L; Blackman SM; Chan CL; Ode KL; Daley T; Stecenko AA; Moran A; Helmick MJ; Cray S; Alvarez JA; Stallings VA; Tuggle KL; Clancy JP; Eggerman TL; Engelhardt JF; Kelly A
Diabetes; 2023 Jun; 72(6):677-689. PubMed ID: 37125945
[TBL] [Abstract][Full Text] [Related]
10. Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.
Grancini V; Gramegna A; Zazzeron L; Alicandro G; Porcaro LL; Piedepalumbo F; Lanfranchi C; Daccò V; Orsi E; Blasi F
Diabetes Metab; 2023 Sep; 49(5):101466. PubMed ID: 37536552
[TBL] [Abstract][Full Text] [Related]
11. A glycosylated hemoglobin A1c above 6% (42 mmol/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis.
Potter KJ; Racine F; Bonhoure A; Boudreau V; Bélanger N; Coriati A; Shohoudi A; Lavoie A; Senior PA; Mailhot G; Rabasa-Lhoret R
Diabetes Metab; 2023 Jul; 49(4):101455. PubMed ID: 37271306
[TBL] [Abstract][Full Text] [Related]
12. Pancreas and islet morphology in cystic fibrosis: clues to the etiology of cystic fibrosis-related diabetes.
Malik SS; Padmanabhan D; Hull-Meichle RL
Front Endocrinol (Lausanne); 2023; 14():1269139. PubMed ID: 38075070
[TBL] [Abstract][Full Text] [Related]
13. The presence of cystic fibrosis-related diabetes modifies the sputum microbiome in cystic fibrosis disease.
Vasiljevs S; Witney AA; Baines DL
Am J Physiol Lung Cell Mol Physiol; 2024 Feb; 326(2):L125-L134. PubMed ID: 38084404
[TBL] [Abstract][Full Text] [Related]
14. Acute soluble fibre supplementation has no impact on reducing post-prandial glucose excursions in adults with cystic fibrosis and glucose intolerance.
Lehoux Dubois C; Boudreau V; Potter KJ; Colomba J; Lavoie A; Mailhot M; Desjardins K; Rabasa-Lhoret R
Ann Endocrinol (Paris); 2023 Dec; 84(6):767-772. PubMed ID: 36764386
[TBL] [Abstract][Full Text] [Related]
15. The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.
Kirigin Biloš LS; Altabas V; Vukić Dugac A; Baretić M
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541202
[TBL] [Abstract][Full Text] [Related]
16. Lived experiences of individuals with cystic fibrosis on CFTR-modulators.
Page A; Goldenberg A; Matthews AL
BMC Pulm Med; 2022 Jan; 22(1):42. PubMed ID: 35062937
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic modifiers of age-related diabetes and neonatal intestinal obstruction in cystic fibrosis.
Aksit MA; Ling H; Pace RG; Raraigh KS; Onchiri F; Faino AV; Pagel K; Pugh E; Stilp AM; Sun Q; Blue EE; Wright FA; Zhou YH; Bamshad MJ; Gibson RL; Knowles MR; Cutting GR; Blackman SM;
Am J Hum Genet; 2022 Oct; 109(10):1894-1908. PubMed ID: 36206743
[TBL] [Abstract][Full Text] [Related]
18. A paradigm shift in cystic fibrosis nutritional care: Clinicians' views on the management of patients with overweight and obesity.
Snowball JE; Flight WG; Heath L; Koutoukidis DA
J Cyst Fibros; 2023 Sep; 22(5):836-842. PubMed ID: 36966039
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis.
Khare S; Desimone M; Kasim N; Chan CL
J Clin Transl Endocrinol; 2022 Mar; 27():100290. PubMed ID: 34917485
[TBL] [Abstract][Full Text] [Related]
20. A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers.
Hicks R; Ode KL; Vigers T; Chan CL
Front Endocrinol (Lausanne); 2023; 14():1183288. PubMed ID: 37274323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
